Jamjoom Pharma 9M 2024 profit up 23% to 304.9M; Q3 at SAR 95M

27/10/2024 Argaam Exclusive

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 304.9 million in 9M 2024, leaping 23% from SAR 247.9 million a year earlier.



Financials (M)

Item 9m 2023 9m 2024 Change‬
Revenues 891.86 1,058.77 18.7 %
Gross Income 584.93 661.99 13.2 %
Operating Income 271.14 326.52 20.4 %
Net Income 247.92 304.92 23.0 %
Average Shares 70.00 70.00 -
EPS (Riyals) 3.54 4.36 23.0 %

The profit increase was buoyed by 18.7% revenue growth year-on-year (YoY) due to higher sales volume in main markets, price adjustment for some products, new product launches, cost management efficiency, and the return on investment in Algeria.



Current Quarter Comparison (M)

Compared With The
Item Q3 2023 Q3 2024 Change‬
Revenues 292.61 327.58 11.9 %
Gross Income 187.23 194.41 3.8 %
Operating Income 84.67 95.67 13.0 %
Net Income 77.25 94.99 23.0 %
Average Shares 70.00 70.00 -
EPS (Riyals) 1.10 1.36 23.0 %

The third-quarter earnings jumped 23% to SAR 95 million, compared to SAR 77.25 million in the year-ago period.

 

On a quarterly basis, the company posted an 11.2% decline in Q3 profit from SAR 106.95 million.

 

Shareholders’ equity, no minority interest, increased to SAR 1.44 billion as of Sept. 30, 2024, compared to SAR 1.36 billion a year earlier.

 

Attached Documents

 

View More Financial Results

 

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co.
157.00
0.80 0.51 %

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

More


Financial Ratios
Current
Market Cap (M Riyal) 10,990.00
Enterprise Value (EV) (M) 10,868.18
Shares Outstanding ((M)) 70.00
EPS ( Riyal) (TTM) 4.99
Book Value (BV) ( Riyal) 20.64
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 31.45
P/E (TTM) 31.45
Price/book 7.61
Return on Average Assets (%) (TTM) 19.9
Return on Average Equity (%) (TTM) 24.9
more


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 121.82 - 77.37 - 14.74 -
Q2 2021 193.05 - 124.75 - 49.73 -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 243.78 100.1 % 164.32 112.4 % 77.42 425.2 %
Q2 2022 238.30 23.4 % 153.06 22.7 % 57.61 15.9 %
Q3 2022 237.76 - 151.13 - 60.03 -
Q4 2022 196.84 - 125.41 - 38.26 -
Q1 2023 300.85 23.4 % 199.61 21.5 % 93.91 21.3 %
Q2 2023 298.40 25.2 % 198.10 29.4 % 92.56 60.7 %
Q3 2023 292.61 23.1 % 187.23 23.9 % 84.67 41.1 %
Q4 2023 207.86 5.6 % 118.86 (5.2 %) 42.24 10.4 %
Q1 2024 385.46 28.1 % 249.40 24.9 % 126.58 34.8 %
Q2 2024 345.74 15.9 % 218.18 10.1 % 104.26 12.6 %
Q3 2024 327.58 11.9 % 194.41 3.8 % 95.67 13.0 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 10.98 - 0.16 - 10.98 0.16
Q2 2021 41.19 - 0.59 - 41.19 0.59
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 43.53 296.3 % 0.62 (28.75) 72.28 1.03
Q2 2022 50.42 22.4 % 0.72 (4.27) 54.69 0.78
Q3 2022 45.60 - 0.65 (7.96) 53.56 0.77
Q4 2022 31.76 - 0.45 (6.98) 38.73 0.55
Q1 2023 84.40 93.9 % 1.21 - 84.40 1.21
Q2 2023 86.27 71.1 % 1.23 - 86.27 1.23
Q3 2023 77.25 69.4 % 1.10 - 77.25 1.10
Q4 2023 44.48 40.1 % 0.64 - 44.48 0.64
Q1 2024 102.97 22.0 % 1.47 - 102.97 1.47
Q2 2024 106.95 24.0 % 1.53 - 106.95 1.53
Q3 2024 94.99 23.0 % 1.36 - 94.99 1.36

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 64.79 % 28.15 % 23.92 %
Q1 2023 64.62 % 28.21 % 23.76 %
Q2 2023 65.22 % 29.98 % 25.44 %
Q3 2023 65.25 % 30.78 % 26.33 %
Q4 2023 64.00 % 30.92 % 26.59 %
Q1 2024 63.63 % 31.58 % 26.26 %
Q2 2024 62.82 % 31.59 % 26.93 %
Q3 2024 61.65 % 31.83 % 27.59 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 70.00 - - -
Q2 2021 70.00 - - 16.98
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 70.00 - - 17.67
Q2 2022 70.00 - - 18.03
Q3 2022 70.00 - - 18.34
Q4 2022 70.00 2.45 3.13 17.38
Q1 2023 70.00 3.03 3.31 18.13
Q2 2023 70.00 3.54 3.76 19.36
Q3 2023 70.00 4.00 4.09 19.45
Q4 2023 70.00 4.18 4.18 20.06
Q1 2024 70.00 4.44 4.44 20.88
Q2 2024 70.00 4.74 4.74 20.90
Q3 2024 70.00 4.99 4.99 20.64

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 25.26 23.82 4.62
Q3 2023 28.98 28.28 5.95
Q4 2023 27.53 27.53 5.73
Q1 2024 28.59 28.59 6.08
Q2 2024 30.69 30.69 6.96
Q3 2024 38.19 38.19 9.24

Business Segments (Million)

Compared With The
Period Pharmaceutical products Consumer Health Products
Q1 2021 107.12 14.70
Q2 2021 174.82 18.23
Q1 2022 203.09 40.70
Q2 2022 207.60 30.70
Q3 2022 206.65 31.11
Q4 2022 180.05 16.79
Q1 2023 258.50 42.35
Q2 2023 256.14 42.26
Q3 2023 251.49 41.12
Q4 2023 189.49 18.36
Q1 2024 334.33 51.13
Q2 2024 299.43 46.30
Q3 2024 282.33 45.24

Analysts Estimates (Million)

Item Q3 2024 (e) Q3 2024 (a) Change‬
Average 98.54 94.99 (3.6 %)

Estimates vs Actual (Million)

Item Q3 2024 (e) Q3 2024 (a) Change
Al Rajhi Capital 91.00 94.99 4.4 %
United Securities Company 100.00 94.99 (5.0) %
OSOOL AND BAKHEET 101.16 94.99 (6.1) %
GIB Capital 102.00 94.99 (6.9) %

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2024, Argaam Investment, All Rights Reserved
Call Request